Lux Launches China BioPharma Intelligence Service

Emerging technology specialist Lux Research has launched the 'China BioPharma Intelligence' service, offering consultancy via a team of analysts based in Shanghai, Singapore and Boston.

Lux provides advice and ongoing intelligence for emerging technologies markets, based on primary research. Its new service will cover emerging technologies and companies, market dynamics and trends, and the regulatory and government landscape.

It will also offer guidance on a wide variety of drug and device development technologies, ranging from stem cells to molecular diagnostics and sensors, medical devices, genomics and proteomics, novel formulation and therapeutics.

According to Lux's analysis of the market, China is planning to increase its investment in the pharmaceutical sector tenfold, through a public-private investment partnership. The country is also responding to a change in business models for western companies seeking to do business in China.

Richard Jun Li, Lux Research Director for China, comments: 'China has made biotechnology and healthcare a major funding prerogative in its long-term R&D strategy. With the 2009-2011 period seeing a cumulative CNY2.6 bn (US$411m) invested across 223 projects, China's spending on basic research funding has risen 30-fold over the past fifteen years.'

Web site: www.luxresearchinc.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Lux Research
• All news